Healthcare Industry News: cutaneous t-cell lymphoma
News Release - January 18, 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
MALVERN, Pa.--(Healthcare Sales & Marketing Network)-- Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris’ investigational drug, chlormethine gel (also known as mechlorethamine gel in the US), for the treatment of cutaneous t-cell lymphoma (CTCL).Orphan Drug Designation is granted by the European Medicines Agency (EMA) to promote the development of products that offer potential therapeutic benefits for diseases affecting less than five in 10,000 people in the EU. Products with Orphan Drug Designation are eligible for ten years of market exclusivity in the EU upon approval.
“The EMA’s decision to grant Orphan Drug Designation to our proprietary mechlorethamine gel underscores the need for additional therapeutic alternatives for patients with cutaneous t-cell lymphoma,” said Ceptaris Chairman of the Board and CEO Steve Tullman. “We look forward to the continued execution of our European regulatory strategy.”
Ceptaris’ mechlorethamine gel is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous t-cell lymphoma (CTCL). The FDA previously granted Orphan Drug Status to this investigational drug. The New Drug Application (NDA) for Ceptaris' mechlorethamine gel was filed in the U.S. in July 2011.
About Ceptaris Therapeutics
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous t-cell lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine gel widely available to relieve the signs and symptoms of this rare cancer. Please visit www.ceptaris.com for more information.
Source: Ceptaris Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
